{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:26:13Z","timestamp":1778005573366,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.mehy.2014.11.020","type":"journal-article","created":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T10:10:57Z","timestamp":1417601457000},"page":"78-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The potential use of cholestyramine to reduce the risk of developing Clostridium difficile-associated diarrhoea in patients receiving long-term intravenous ceftriaxone"],"prefix":"10.1016","volume":"84","author":[{"given":"B.K.","family":"Puri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.S.","family":"Hakkarainen-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean A.","family":"Monro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2014.11.020_b0005","doi-asserted-by":"crossref","first-page":"e61666","DOI":"10.1371\/journal.pone.0061666","article-title":"The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2014.11.020_b0010","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00115-003-1560-z","article-title":"Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone","volume":"75","author":"Kaiser","year":"2004","journal-title":"Nervenarzt"},{"key":"10.1016\/j.mehy.2014.11.020_b0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/BF01780667","article-title":"Ceftriaxone in the treatment of Lyme neuroborreliosis","volume":"24","author":"Rohacova","year":"1996","journal-title":"Infection"},{"key":"10.1016\/j.mehy.2014.11.020_b0020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jama.1993.03500080027010","article-title":"Ceftriaxone-associated biliary complications of treatment of suspected disseminated Lyme disease-New Jersey, 1990\u20131992","volume":"269","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2014.11.020_b0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/infdis\/163.2.311","article-title":"Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis","volume":"163","author":"Pfister","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mehy.2014.11.020_b0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jinf.2012.12.004","article-title":"Intravenous ceftriaxone, followed by 12 or three months of oral treatment with trimethoprim-sulfamethoxazole in Whipple\u2019s disease","volume":"66","author":"Feurle","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.mehy.2014.11.020_b0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0072-9752(09)96012-2","article-title":"Spirochetal infections","volume":"96","author":"Cadavid","year":"2010","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.mehy.2014.11.020_b0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/AAC.35.1.208","article-title":"Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery","volume":"35","author":"Privitera","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2014.11.020_b0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-4453(91)93656-W","article-title":"Clostridium difficile in faecal flora after perioperative prophylaxis with ampicillin or ceftriaxone","volume":"23","author":"Westh","year":"1991","journal-title":"J Infect"},{"key":"10.1016\/j.mehy.2014.11.020_b0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11739-011-0653-0","article-title":"Use and indications of cholestyramine and bile acid sequestrants","volume":"8","author":"Scaldaferri","year":"2013","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.mehy.2014.11.020_b0055","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1089\/thy.2008.0094","article-title":"Dramatic response to cholestyramine in a patient with Graves\u2019 disease resistant to conventional therapy","volume":"18","author":"Sebastian-Ochoa","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.mehy.2014.11.020_b0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12020-008-9107-5","article-title":"Low doses of cholestyramine in the treatment of hyperthyroidism","volume":"34","author":"Kaykhaei","year":"2008","journal-title":"Endocrine"},{"key":"10.1016\/j.mehy.2014.11.020_b0065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000111083","article-title":"Phase II clinical trial for prevention of delayed diarrhea with cholestyramine\/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma","volume":"72","author":"Flieger","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.mehy.2014.11.020_b0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0167-4838(01)00138-8","article-title":"Analysis of the physicochemical interactions between Clostridium difficile toxins and cholestyramine using liquid chromatography with post-column derivatization","volume":"1546","author":"Palace","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mehy.2014.11.020_b0075","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/toxins6072162","article-title":"The combined repetitive oligopeptides of Clostridium difficile toxin A counteract premature cleavage of the glucosyl-transferase domain by stabilizing protein conformation","volume":"6","author":"Olling","year":"2014","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.mehy.2014.11.020_b0080","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/IAI.01950-14","article-title":"An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo","volume":"82","author":"Baliban","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.mehy.2014.11.020_b0085","series-title":"British national formulary","year":"2014"},{"key":"10.1016\/j.mehy.2014.11.020_b0090","series-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","first-page":"877","article-title":"Drug therapy for hypercholesterolemia and dyslipidemia","author":"Bersot","year":"2011"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987714004344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987714004344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:32:30Z","timestamp":1717601550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987714004344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0306987714004344"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2014.11.020","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential use of cholestyramine to reduce the risk of developing Clostridium difficile-associated diarrhoea in patients receiving long-term intravenous ceftriaxone","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2014.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}